Application note: Hyperion+ imaging system
A powerful tool to study complex phenotypes and cellular interactions. Map spatial interactions twice as fast with this second-generation system.
List view / Grid view
A powerful tool to study complex phenotypes and cellular interactions. Map spatial interactions twice as fast with this second-generation system.
7 September 2022 | By Sartorius
Watch this webinar to hear from Dr Yuansheng Yang as he introduces a CHO cell-based technology allowing simultaneous display and secretion of antibodies for accelerating the process of antibody development.
Scientists have discovered antibodies that are effective against many different COVID-19 variants.
Application note: Quantifying T Cell response in 3D tumour spheroids using advanced flow cytometry workflows.
Vaccinating mice with this universal flu candidate induced broad neuraminidase inhibition, M2 ectodomain specific antibodies and T cell immune responses.
Researchers have designed a COVID-19 vaccine to be less sensitive to mutations and equipped for future strains.
Scientists have identified and synthesised a small molecule that could be a more accessible and affective alternative to an antibody that treats a wide range of cancers.
19 August 2022 | By Sartorius
Want to learn about the latest research and development of cell models in rare diseases? Then watch this virtual panel discussion to hear from industry experts.
This publications review overviews advanced flow cytometry applications in infectious disease and immuno-oncology.
Learn about current and emerging immune checkpoint molecules that are being investigated as potential immuno-oncology targets.
Learn about DLS, a powerful method to characterise the purity and aggregation state of your biologics for improved candidate selection.
Researchers have developed a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection.
R&D Systems offers custom antibody production services to engineer the right antibody to solve your research question with confidence.
The vaccine attaches spike proteins from SARS-CoV-2 and seven other SARS-like betacoronaviruses to a protein nanoparticle structure, to induce the production of a broad spectrum of cross-reactive antibodies.
The monoclonal antibody 19A11 binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.